Overview

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.
Phase:
Phase 3
Details
Lead Sponsor:
Foundation for Liver Research
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin